|1.||Soares-da-Silva, Patrício: 11 articles (03/2015 - 03/2007)|
|2.||Almeida, Luis: 11 articles (03/2015 - 03/2007)|
|3.||Falcão, Amílcar: 7 articles (03/2015 - 07/2007)|
|4.||Soares-da-Silva, Patricio: 7 articles (02/2014 - 01/2010)|
|5.||Nunes, Teresa: 6 articles (03/2015 - 08/2008)|
|6.||Maia, Joana: 6 articles (10/2010 - 03/2007)|
|7.||Soares-da-Silva, P: 5 articles (09/2011 - 05/2001)|
|8.||Blum, David: 4 articles (12/2015 - 01/2015)|
|9.||Elger, Christian: 4 articles (01/2013 - 03/2007)|
|10.||Almeida, L: 4 articles (09/2011 - 04/2009)|
09/01/2014 - "Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study."
02/01/2013 - "To evaluate the long-term safety, tolerability and efficacy of once-daily eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial-onset seizures. "
12/01/2015 - "The objective of this study was to compare posttreatment seizure severity in a phase III clinical trial of eslicarbazepine acetate (ESL) as adjunctive treatment of refractory partial-onset seizures. "
12/01/2015 - "Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate."
07/01/2015 - "All performed studies have consistently shown that eslicarbazepine acetate (800 to 1200 mg/day) is effective and well tolerated as adjunctive therapy for adults with partial-onset seizures. "
01/01/2009 - "* Long-term treatment with eslicarbazepine acetate significantly improved from baseline health-related quality of life as assessed by the Quality-of-Life in Epilepsy Inventory-31 instrument. "
02/01/2015 - "We found that eslicarbazepine acetate exhibits strong antiepileptogenic effects in experimental epilepsy. "
05/26/2014 - "Eslicarbazepine acetate (aptiom) for epilepsy."
01/01/2014 - "To explore a possible link between the treatment of AD and epilepsy, the molecular interactions of recently Food and Drug Administration approved antiepileptic drug Aptiom (Eslicarbazepine acetate) with BACE and VSC were studied. "
01/01/2014 - "Eslicarbazepine acetate: an update on efficacy and safety in epilepsy."
|3.||Partial Epilepsies (Epilepsy, Partial)
01/01/2014 - "This article provides an overview on the recent studies on eslicarbazepine acetate in the treatment of drug-resistant partial epilepsy. "
03/01/2015 - "Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action."
05/01/2012 - "Eslicarbazepine acetate is an alternative treatment in associated therapy in patients with partial epilepsy who do not respond adequately to treatment in monotherapy."
06/01/2011 - "Eslicarbazepine acetate (ESL) was labelled for add-on treatment of adults with focal epilepsies in 2009. "
01/01/2011 - "In this review we summarized the current evidence regarding eslicarbazepine acetate (ESL) when used as an add-on treatment for drug-resistant partial epilepsy. "
|5.||Bipolar Disorder (Mania)
03/15/2015 - "Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I."
11/01/2012 - "Eslicarbazepine acetate in the management of refractory bipolar disorder."
11/01/2007 - "Eslicarbazepine acetate (BIA 2-093) is a novel central nervous system drug undergoing clinical phase III trials for epilepsy and phase II trials for bipolar disorder. "
07/01/2007 - "To determine the effect of gender on the pharmacokinetics of eslicarbazepine acetate, a novel voltage-gated sodium channel blocker in the development for the treatment of epilepsy and bipolar disorder. "
|1.||Sodium Channels (Sodium Channel)
|2.||Calcium Channels (Calcium Channel)
|3.||Cannabinoid Receptors (Cannabinoid Receptor)
|5.||Anticonvulsants (Antiepileptic Drugs)
|8.||D 23129 (retigabine)
|1.||Electric Stimulation Therapy (Electrotherapy)